173 related articles for article (PubMed ID: 36249062)
1. Novel irreversible electroporation ablation (Nano-knife) versus radiofrequency ablation for the treatment of solid liver tumors: a comparative, randomized, multicenter clinical study.
Zhang X; Zhang X; Ding X; Wang Z; Fan Y; Chen G; Hu X; Zheng J; Xue Z; He X; Zhang X; Wei Y; Zhang Z; Li J; Li J; Yang J; Xue X; Ma L; Xiao Y
Front Oncol; 2022; 12():945123. PubMed ID: 36249062
[TBL] [Abstract][Full Text] [Related]
2. Biliary complications and efficacy after ablation of peribiliary tumors using irreversible electroporation (IRE) or radiofrequency ablation (RFA).
Thamtorawat S; Patanawanitkul R; Rojwatcharapibarn S; Chaiyasoot W; Tongdee T; Yodying J; Sorotpinya S
Int J Hyperthermia; 2022; 39(1):751-757. PubMed ID: 35649727
[TBL] [Abstract][Full Text] [Related]
3. Irreversible electroporation versus radiofrequency ablation for hepatocellular carcinoma: a single centre propensity-matched comparison.
Freeman E; Cheung W; Ferdousi S; Kavnoudias H; Majeed A; Kemp W; Roberts SK
Scand J Gastroenterol; 2021 Aug; 56(8):942-947. PubMed ID: 34057003
[TBL] [Abstract][Full Text] [Related]
4. Similar complication rates for irreversible electroporation and thermal ablation in patients with hepatocellular tumors.
Verloh N; Jensch I; Lürken L; Haimerl M; Dollinger M; Renner P; Wiggermann P; Werner JM; Zeman F; Stroszczynski C; Beyer LP
Radiol Oncol; 2019 Mar; 53(1):116-122. PubMed ID: 30840591
[TBL] [Abstract][Full Text] [Related]
5. Irreversible electroporation versus radiofrequency ablation for malignant hepatic tumor: A prospective single-center double-arm trial.
Liu B; Fu D; Fan Y; Wang Z; Lang X
J Interv Med; 2022 May; 5(2):89-94. PubMed ID: 35936662
[TBL] [Abstract][Full Text] [Related]
6. Tumor Ablation Enhancement by Combining Radiofrequency Ablation and Irreversible Electroporation: An In Vitro 3D Tumor Study.
Zhang B; Yang Y; Ding L; Moser MAJ; Zhang EM; Zhang W
Ann Biomed Eng; 2019 Mar; 47(3):694-705. PubMed ID: 30565007
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Chronologic Change in the Size and Contrast-Enhancement of Ablation Zones on CT Images after Irreversible Electroporation and Radiofrequency Ablation.
Scheck J; Bruners P; Schindler D; Kuhl C; Isfort P
Korean J Radiol; 2018; 19(4):560-567. PubMed ID: 29962862
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of Radiofrequency Ablation, Microwave Ablation, and Irreversible Electroporation by Using Propensity Score Analysis for Early Stage Hepatocellular Carcinoma.
Wada T; Sugimoto K; Sakamaki K; Takahashi H; Kakegawa T; Tomita Y; Abe M; Yoshimasu Y; Takeuchi H; Itoi T
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765689
[TBL] [Abstract][Full Text] [Related]
9. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results.
Frühling P; Nilsson A; Duraj F; Haglund U; Norén A
Eur J Surg Oncol; 2017 Apr; 43(4):751-757. PubMed ID: 28109674
[TBL] [Abstract][Full Text] [Related]
10. Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation.
He C; Wang J; Zhang Y; Cai Z; Lin X; Li S
Cancer Med; 2020 Jul; 9(13):4699-4710. PubMed ID: 32410380
[TBL] [Abstract][Full Text] [Related]
11. The Accumulation and Effects of Liposomal Doxorubicin in Tissues Treated by Radiofrequency Ablation and Irreversible Electroporation in Liver: In Vivo Experimental Study on Porcine Models.
Andrašina T; Jaroš J; Jůza T; Rohan T; Červinka D; Crha M; Válek V; Goldberg NS
Cardiovasc Intervent Radiol; 2019 May; 42(5):751-762. PubMed ID: 30761413
[TBL] [Abstract][Full Text] [Related]
12. Midterm Safety and Efficacy of Irreversible Electroporation of Malignant Liver Tumors Located Close to Major Portal or Hepatic Veins.
Distelmaier M; Barabasch A; Heil P; Kraemer NA; Isfort P; Keil S; Kuhl CK; Bruners P
Radiology; 2017 Dec; 285(3):1023-1031. PubMed ID: 28799842
[TBL] [Abstract][Full Text] [Related]
13. Pain After Percutaneous Irreversible Electroporation of Renal Tumors Is Not Dependent on Tumor Location.
Sorokin I; Lay AH; Reddy NK; Canvasser NE; Chamarthy M; Cadeddu JA
J Endourol; 2017 Aug; 31(8):751-755. PubMed ID: 28586250
[TBL] [Abstract][Full Text] [Related]
14. Irreversible electroporation of hepatocellular carcinoma: the role of ultrasonography.
Sugimoto K; Abe M; Yoshimasu Y; Takeuchi H; Kasai Y; Itoi T
Ultrasonography; 2020 Jul; 39(3):229-237. PubMed ID: 32450674
[TBL] [Abstract][Full Text] [Related]
15. Pain analysis in patients with hepatocellular carcinoma: irreversible electroporation versus radiofrequency ablation-initial observations.
Narayanan G; Froud T; Lo K; Barbery KJ; Perez-Rojas E; Yrizarry J
Cardiovasc Intervent Radiol; 2013 Feb; 36(1):176-82. PubMed ID: 22752100
[TBL] [Abstract][Full Text] [Related]
16. Irreversible Electroporation Enhanced by Radiofrequency Ablation: An In Vitro and Computational Study in a 3D Liver Tumor Model.
Fang Z; Mao H; Moser MAJ; Zhang W; Qian Z; Zhang B
Ann Biomed Eng; 2021 Sep; 49(9):2126-2138. PubMed ID: 33594637
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of CT-guided percutaneous irreversible electroporation (IRE) ablation: clinical efficacy and safety.
Wang Z; Lu J; Huang W; Wu Z; Gong J; Wang Q; Liu Q; Wang C; Zhu Y; Ding X; Wang Z
BMC Cancer; 2021 Feb; 21(1):124. PubMed ID: 33546635
[TBL] [Abstract][Full Text] [Related]
18. Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnife® system for the ablation of stage 3 pancreatic adenocarcinoma: overview of study protocols.
Narayanan G; Bilimoria MM; Hosein PJ; Su Z; Mortimer KM; Martin RCG
BMC Cancer; 2021 Jul; 21(1):785. PubMed ID: 34233640
[TBL] [Abstract][Full Text] [Related]
19. Irreversible Electroporation For Liver Tumors: A Review Of Literature.
Tameez Ud Din A; Tameez-Ud-Din A; Chaudhary FMD; Chaudhary NA; Siddiqui KH
Cureus; 2019 Jun; 11(6):e4994. PubMed ID: 31497425
[TBL] [Abstract][Full Text] [Related]
20. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial.
Kim TH; Koh YH; Kim BH; Kim MJ; Lee JH; Park B; Park JW
J Hepatol; 2021 Mar; 74(3):603-612. PubMed ID: 33031846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
